Kristin Kiehn

Debevoise & Plimpton LLP 

Kristin D. Kiehn is a counsel in the firm’s Litigation Department, based in the New York office. Her practice focuses on healthcare-related enforcement, litigation and compliance, including in the areas of white collar and regulatory defense, government and internal investigations, general commercial litigation, and compliance and regulatory advice.

She has broad experience representing pharmaceutical and medical device companies, hospitals, pharmacies, and individuals in a variety of healthcare-related matters, including government investigations relating to sales and marketing practices, manufacturing and distribution issues, clinical trials, healthcare program reporting, and individual Park liability; False Claims Act litigation and consumer and third-party payor class actions alleging deceptive practices; and international disputes relating to drug development, manufacturing, and safety.

Her experience includes healthcare program exclusion matters and Corporate Integrity Agreement negotiation and implementation. She regularly advises clients – including major pharmaceutical and device companies – on corporate compliance standards and best practices in the healthcare industry.

Ms. Kiehn is the co-author of numerous articles, including “A Walk in the Park Shouldn’t Lead to Jail Time: Recent Decisions Explain Why Incarceration is Never Appropriate for ‘Responsible Corporate Officers’ Who Lack Criminal Intent,” Bloomberg BNA’s Pharmaceutical Law & Industry Report (October, 2016); “It’s A Hard-Knock Life: The Rough-And-Tumble Fight Over Orphan Drug Pricing,” Bloomberg BNA’s Pharmaceutical Law & Industry Report (November, 2014); “DOJ Proposal Shows Focus on Individuals in Corporate Crime,” Law360 (September, 2014); “Compliance Corner: The Clock Is Ticking: 60-Day Rule and FCA Liability for Overpayments,” Bloomberg BNA’s Health Care Fraud Report (September, 2014); “Vicarious Criminal Liability in the Executive Suite for Problems on the Manufacturing Floor,” Bloomberg BNA’s Pharmaceutical Law & Industry Report(April, 2014); “GSK’s $3 Billion Settlement Reflects Continued Expansion In Scope Of Pharma Plea Agreements,” Rx Compliance Report (August, 2012) and “An Unprecedented Settlement For FDCA Violation,” Law360 (May, 2012).

Ms. Kiehn joined the firm in 2001, then rejoined the firm in 2003. From 2000 to 2001, she clerked for the Hon. John S. Martin, Jr., Southern District of New York. From 2002 to 2003, she clerked for the Hon. Chester J. Straub, U.S. Court of Appeals for the Second Circuit.

Ms. Kiehn received a J.D. cum laude from Fordham University School of Law in 2000. She was writing & research editor of the Fordham Law Review. Ms. Kiehn received an M.A. from New York University in 1996, and a B.A. from Smith College in 1992.

Prior to coming to the firm, Ms. Kiehn worked in the publishing field.


  • A major pharmaceutical company in defeating nine motions to certify classes of consumers and third-party payors and obtaining dismissal of all remaining claims in MDL actions alleging RICO and consumer fraud violations based on alleged fraudulent promotion of antidepressants.
  • A major pharmaceutical company in obtaining dismissal of qui tam action under the False Claims Act relating to marketing of prescription drug due to unethical behavior by relator’s counsel. In its dismissal, the district court, in addressing a novel legal issue, admonished counsel for obtaining medical information from physicians by engaging in “an elaborate scheme of deceptive conduct.”
  • A major pharmaceutical company in obtaining dismissal of state law claims in First Circuit decision marking the first time since Wyeth v. Levine that a federal appellate court dismissed claims against a brand-name drug manufacturer pursuant to the “impossibility” preemption doctrine.
  • A major pharmaceutical company in civil and criminal investigations led by DOJ and the U.S. Attorney’s Office (D. of Mass.), and related qui tam litigation, regarding marketing, promotion, and sale of three drugs.
  • A major pharmaceutical company in investigation led by DOJ and the U.S. Attorney’s Office (E.D. of Wisconsin) relating to speaker programs involving three prescription drugs.
  • A major pharmaceutical company in investigation led by DOJ and the U.S. Attorney’s Office (D. Mass.) relating to marketing of cardiovascular drugs.
  • A national pharmacy chain in investigation led by the U.S. Attorney’s Office (SDNY) relating to billing practices.
  • A major pharmaceutical company in obtaining dismissal of qui tam action under the False Claims Act alleging kickbacks paid to physicians in connection with marketing of several drugs.
  • A major U.S. hospital network in defending multiple class action complaints filed in several states alleging wrongful billing practices.
  • A multinational healthcare company executive in investigations led by DOJ, the U.S. Attorney’s Office (E.D. Pa.), and U.S. Congress arising from consumer product recalls.
    A major pharmaceutical company in negotiating, implementing, and facilitating ongoing compliance with Corporate Integrity Agreement.
  • A multinational pharmaceutical company’s Board of Directors in conducting several Compliance Program effectiveness reviews to support Corporate Integrity Agreement obligations.
  • The Board of Directors of a leading medical device manufacturer in conducting several Compliance Program effectiveness reviews to support obligations under a plea agreement.
  • The CEO and Chief Compliance Officer of a global pharmaceutical company in meeting obligations under a Corporate Integrity Agreement.
  • A pharmaceutical company in providing compliance advice relating to marketing of drugs for rare diseases.


  • Fordham University School of Law, 2000, J.D.
  • New York University, 1996, M.A.
  • Smith College, 1992, B.A.

Bar Admissions:

  • New York


Rate : $$$

What types of cases Attorney Kristin Kiehn & Debevoise & Plimpton LLP  can handle?
Debevoise & Plimpton LLP  can handle cases related to laws concerning Litigation, White Collar Crime, Health Care. We manually verify each attorney’s practice areas before approving their profiles and reviews on our website.
Where is Debevoise & Plimpton LLP  located?
Debevoise & Plimpton LLP  is located at 919 Third Avenue, New York, NY 10022, USA. You can reach out to Debevoise & Plimpton LLP  using their phone line 212 909 6846. You can also check their website or email them at [email protected].
How much would it cost to hire Debevoise & Plimpton LLP ?
Kristin Kiehn lawyer charges are specific to each case. However, they work with contingency fees and its ranges from $$ to $$$. They also provide free consultation [and no obligation quotes] if you are interested to hire.
Are Kristin Kiehn reviews trust-able?
We have the ratings and reviews moderation team who checks and verifies every review submitted on our website manually. You can trust all the reviews you see on Kristin Kiehn lawyer profile listing.

Rate and write a review

Your email address will not be published. Required fields are marked *

Is this your profile?Claim it now.

Make sure your information is up to date.
Debevoise & Plimpton LLP 
919 Third Avenue, New York, NY 10022, USA
Get directions

Tyler Nicoll

Crosspointe Drive 1019
Naples 34110 FL US

Rick Cofer

West Avenue 1002
Austin 78701 TX US

Brian Orlow

Main Street 71-18
11367 NY US

Lina Stillman

Broadway 42
New York 10006 NY US